JP2007504128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504128A5 JP2007504128A5 JP2006524603A JP2006524603A JP2007504128A5 JP 2007504128 A5 JP2007504128 A5 JP 2007504128A5 JP 2006524603 A JP2006524603 A JP 2006524603A JP 2006524603 A JP2006524603 A JP 2006524603A JP 2007504128 A5 JP2007504128 A5 JP 2007504128A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- independently selected
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 102000016799 Leukocyte elastase Human genes 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302323A SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Novel compounds |
| PCT/SE2004/001226 WO2005021509A1 (en) | 2003-08-28 | 2004-08-25 | Quinoline derivatives as neutrophil elastase inhibitors and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504128A JP2007504128A (ja) | 2007-03-01 |
| JP2007504128A5 true JP2007504128A5 (enExample) | 2007-09-06 |
Family
ID=28673217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524603A Pending JP2007504128A (ja) | 2003-08-28 | 2004-08-25 | 好中球エラスターゼ阻害剤としてのキノリン誘導体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070010551A1 (enExample) |
| EP (1) | EP1660452A1 (enExample) |
| JP (1) | JP2007504128A (enExample) |
| CN (1) | CN100427469C (enExample) |
| SE (1) | SE0302323D0 (enExample) |
| WO (1) | WO2005021509A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| ATE509925T1 (de) * | 2006-11-17 | 2011-06-15 | Pfizer | Substituierte bicyclocarbonsäureamidverbindungen |
| WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| AU2010302420B2 (en) * | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| CN103058927B (zh) * | 2011-10-21 | 2015-04-22 | 华国媛 | 一种喹啉衍生物及其应用 |
| SG11201401937YA (en) | 2011-11-04 | 2014-05-29 | Hoffmann La Roche | New aryl-quinoline derivatives |
| CN104994857A (zh) * | 2012-10-11 | 2015-10-21 | 格吕伦塔尔有限公司 | Tspo介导的疾病和/或障碍的治疗和/或预防 |
| CN105726538A (zh) * | 2016-03-28 | 2016-07-06 | 张雪燕 | 一种抗肺纤维化的药物组合物及其应用 |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| AU2020349353A1 (en) | 2019-09-17 | 2022-04-14 | Duke University | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| HUE064089T2 (hu) | 2020-04-16 | 2024-02-28 | Mereo Biopharma 4 Ltd | Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére |
| AU2022373971A1 (en) | 2021-10-20 | 2024-04-04 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| ZA794209B (en) * | 1978-08-15 | 1980-07-30 | Fisons Ltd | Pharmaceutically active heterocyclic compounds |
| EP0008864A1 (en) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| JPH02152966A (ja) * | 1988-12-05 | 1990-06-12 | Otsuka Pharmaceut Co Ltd | ４−ヒドロキシカルボスチリル誘導体 |
| JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| US5441960A (en) * | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
| JP2001192398A (ja) * | 1996-12-06 | 2001-07-17 | Cortech Inc | セリンプロテアーゼ阻害剤 |
| JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| EP1048655B1 (en) * | 1997-12-03 | 2004-09-01 | Taisho Pharmaceutical Co., Ltd | 1,2-dihydro-2-oxoquinoline derivatives |
| WO2001096308A1 (en) * | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| DE60139506D1 (de) * | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-08-28 SE SE0302323A patent/SE0302323D0/xx unknown
-
2004
- 2004-08-25 JP JP2006524603A patent/JP2007504128A/ja active Pending
- 2004-08-25 US US10/569,571 patent/US20070010551A1/en not_active Abandoned
- 2004-08-25 EP EP04775332A patent/EP1660452A1/en not_active Withdrawn
- 2004-08-25 WO PCT/SE2004/001226 patent/WO2005021509A1/en not_active Ceased
- 2004-08-25 CN CNB2004800249875A patent/CN100427469C/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10195186B2 (en) | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | |
| US20040259842A1 (en) | Intracellular calcuim concentration increase inhibitors | |
| EP4143193B1 (en) | Imidazopyrimidines as modulators of il-17 | |
| JP2000505063A (ja) | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 | |
| WO2006064757A1 (ja) | アミノカルボン酸誘導体およびその医薬用途 | |
| JP2009543836A (ja) | インドール化合物 | |
| EP1369419B1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
| JP7089596B2 (ja) | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 | |
| JP2015534554A (ja) | アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物 | |
| JPS63152388A (ja) | 新規なセフェム化合物 | |
| WO2020262603A1 (ja) | Ｅｐ２アンタゴニスト | |
| JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
| HUP0004020A2 (hu) | Triciklusos triazolo-benzazepin-származékok, eljárás a vegyületek előállítására és alkalmazásuk antiallergiás szerként | |
| WO2006043655A1 (ja) | 吸入用医薬組成物 | |
| BE898383A (fr) | Pyrazoloquinoleines substituees particulieres, procede pour leur preparation, preparations pharmaceutiques contenant ces composes et leur application therapeutique. | |
| CN114364665B (zh) | 调节白介素的前药 | |
| JPS6058747B2 (ja) | アミノ化合物の製法 | |
| CA2080340A1 (fr) | Derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| JP7312745B2 (ja) | アゼチジン誘導体及びそのプロドラッグ | |
| CN111372579A (zh) | 取代的苯基磺酰基苯基三唑硫酮和其用途 | |
| CH646976A5 (de) | 7-alpha-methoxycephalosporine und verfahren zur herstellung derselben. | |
| WO2023247958A1 (en) | Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases | |
| CN101573321A (zh) | 二羟基蒽醌羧酸盐及其治疗用途 | |
| JP7025542B2 (ja) | Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール | |
| JPS63239274A (ja) | 新規なイミダゾ−ル誘導体およびその塩 |